Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-13 2:59 pm Sale |
2024-09-30 | 13G | Kinnate Biopharma Inc. KNTE |
Vida Ventures LLC | 0 0.000% |
-2,207,772 (Position Closed) |
Filing History |
| 2024-04-05 4:15 pm Sale |
2024-04-03 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund V L.P. | 0 0.000% |
-13,779,062 (Position Closed) |
Filing History |
| 2024-02-22 4:39 pm Unchanged |
2024-02-16 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund V L.P. | 13,779,062 29.200% |
0 (Unchanged) |
Filing History |
| 2024-02-21 4:11 pm Unchanged |
2024-02-16 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 7,559,729 16.100% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:16 pm Sale |
2023-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
Nextech V Oncology S.C.S. SICAV-SIF | 0 0.000% |
-2,329,480 (Position Closed) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
TANG CAPITAL PARTNERS LP | 2,601,647 5.500% |
-364,068 (-12.28%) |
Filing History |
| 2024-02-14 09:21 am Sale |
2023-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
Lynx1 Capital Management LP | 1,997,006 4.200% |
-216,172 (-9.77%) |
Filing History |
| 2023-11-27 4:47 pm Purchase |
2023-11-15 | 13G | Kinnate Biopharma Inc. KNTE |
TANG CAPITAL PARTNERS LP | 2,965,715 6.300% |
2,965,715 (New Position) |
Filing History |
| 2023-11-17 08:27 am Unchanged |
2023-11-17 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 7,559,729 16.000% |
0 (Unchanged) |
Filing History |
| 2023-11-17 08:00 am Unchanged |
2023-11-17 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund V L.P. | 13,779,062 29.200% |
0 (Unchanged) |
Filing History |
| 2023-11-14 4:57 pm Unchanged |
2023-11-13 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 7,559,729 16.000% |
0 (Unchanged) |
Filing History |
| 2023-11-14 4:30 pm Purchase |
2023-11-13 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund V L.P. | 13,779,062 29.200% |
13,779,062 (New Position) |
Filing History |
| 2023-08-14 5:00 pm Sale |
2023-08-14 | 13G | Kinnate Biopharma Inc. KNTE |
RA Capital Management, L.P. | 0 0.000% |
-4,264,144 (Position Closed) |
Filing History |
| 2023-05-10 5:20 pm Purchase |
2023-05-08 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund IV, L.P. | 13,718,311 29.500% |
1,780,000 (+14.91%) |
Filing History |
| 2023-05-08 5:01 pm Purchase |
2023-05-04 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 7,559,729 16.200% |
1,460,932 (+23.95%) |
Filing History |
| 2023-05-02 7:28 pm Purchase |
2023-04-28 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 6,098,797 13.100% |
1,405,168 (+29.94%) |
Filing History |
| 2023-04-06 09:29 am Sale |
2023-03-31 | 13G | Kinnate Biopharma Inc. KNTE |
BLACKROCK INC BLK |
2,277,109 4.900% |
-58,709 (-2.51%) |
Filing History |
| 2023-02-23 3:23 pm Purchase |
2023-02-17 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 4,693,629 10.600% |
1,295,700 (+38.13%) |
Filing History |
| 2023-02-22 3:01 pm Purchase |
2023-02-17 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund IV, L.P. | 11,938,311 25.600% |
1,100,000 (+10.15%) |
Filing History |
| 2023-02-14 4:45 pm Purchase |
2022-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
RA Capital Management, L.P. | 4,264,144 9.700% |
671,092 (+18.68%) |
Filing History |